학술논문
Low prevalence of influenza A strains with resistance markers in Brazil during 2017–2019 seasons
Document Type
article
Author
Thiago das Chagas Sousa; Jessica Santa Cruz Carvalho Martins; Milene Dias Miranda; Cristiana Couto Garcia; Paola Cristina Resende; Cliomar A. Santos; Maria do Carmo Debur; Rodrigo Ribeiro Rodrigues; Andrea Cony Cavalcanti; Tatiana Schäffer Gregianini; Felipe Campos de Melo Iani; Felicidade Mota Pereira; Sandra Bianchini Fernandes; Jessylene de Almeida Ferreira; Katia Correa de Oliveira Santos; Fernando Motta; David Brown; Walquiria Aparecida Ferreira de Almeida; Marilda Mendonça Siqueira; Aline da Rocha Matos
Source
Frontiers in Public Health, Vol 10 (2022)
Subject
Language
English
ISSN
2296-2565
Abstract
The influenza A virus (IAV) is of a major public health concern as it causes annual epidemics and has the potential to cause pandemics. At present, the neuraminidase inhibitors (NAIs) are the most widely used anti-influenza drugs, but, more recently, the drug baloxavir marboxil (BXM), a polymerase inhibitor, has also been licensed in some countries. Mutations in the viral genes that encode the antiviral targets can lead to treatment resistance. Worldwide, a low prevalence of antiviral resistant strains has been reported. Despite that, this situation can change rapidly, and resistant strain surveillance is a priority. Thus, the aim of this was to evaluate Brazilian IAVs antiviral resistance from 2017 to 2019 through the identification of viral mutations associated with reduced inhibition of the drugs and by testing the susceptibility of IAV isolates to oseltamivir (OST), the most widely used NAI drug in the country. Initially, we analyzed 282 influenza A(H1N1)pdm09 and 455 A(H3N2) genetic sequences available on GISAID. The amino acid substitution (AAS) NA:S247N was detected in one A(H1N1)pdm09 strain. We also identified NA:I222V (n = 6) and NA:N329K (n = 1) in A(H3N2) strains. In addition, we performed a molecular screening for NA:H275Y in 437 A(H1N1)pdm09 samples, by pyrosequencing, which revealed a single virus harboring this mutation. Furthermore, the determination of OST IC50 values for 222 A(H1N1)pdm09 and 83 A(H3N2) isolates revealed that all isolates presented a normal susceptibility profile to the drug. Interestingly, we detected one A(H3N2) virus presenting with PA:E119D AAS. Moreover, the majority of the IAV sequences had the M2:S31N adamantanes resistant marker. In conclusion, we show a low prevalence of Brazilian IAV strains with NAI resistance markers, in accordance with what is reported worldwide, indicating that NAIs still remain an option for the treatment of influenza infections in Brazil. However, surveillance of influenza resistance should be strengthened in the country for improving the representativeness of investigated viruses and the robustness of the analysis.